Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Acta Neuropathol. 2016 Apr 8;132(1):59–75. doi: 10.1007/s00401-016-1572-y

Fig. 9.

Fig. 9

No alteration of oligodendrocyte density by benztropine. a Oligodendrocytic cells within the corpus callosum were identified using stage specific markers (entire population: Olig2; oligodendrocyte progenitor cells: platelet-derived growth factor receptor-α (Pdgfrα)/Olig2strong (arrowhead), mature oligodendrocytes: glutathione-s-transferase-π (Gstπ)/Olig2weak, as well as cells staining for Olig2strong only (asterisk)). Scale bar: 20μm. b A profound increase of oligodendrocytic cells within the corpus callosum of mice overexpressing α-synuclein in oligodendrocytes (MBP29) compared to non-transgenic controls (NTG) was observed. Scale bar: 20μm. c While MBP29 mice exhibited an almost 2-fold increased density of the entire spectrum of oligodendrocytic subpopulations, benztropine (BT) had no effect on oligodendrocytic cell density as compared to vehicle (veh)-treatment. Data are shown as mean ± standard error of mean. ANOVA (n = 5): **p < 0.01, ***p < 0.001. T-test: not significant (n.s.) p > 0.05.